WO2012027794A3 - Method of treatment and agents useful for same - Google Patents
Method of treatment and agents useful for same Download PDFInfo
- Publication number
- WO2012027794A3 WO2012027794A3 PCT/AU2011/001132 AU2011001132W WO2012027794A3 WO 2012027794 A3 WO2012027794 A3 WO 2012027794A3 AU 2011001132 W AU2011001132 W AU 2011001132W WO 2012027794 A3 WO2012027794 A3 WO 2012027794A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- precursor protein
- amyloid precursor
- treatment
- same
- agents useful
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- 238000011282 treatment Methods 0.000 title abstract 2
- 101710137189 Amyloid-beta A4 protein Proteins 0.000 abstract 4
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 abstract 4
- 102100022704 Amyloid-beta precursor protein Human genes 0.000 abstract 4
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 abstract 4
- 108010075016 Ceruloplasmin Proteins 0.000 abstract 3
- 102100023321 Ceruloplasmin Human genes 0.000 abstract 3
- 230000000694 effects Effects 0.000 abstract 3
- 230000001594 aberrant effect Effects 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000003993 interaction Effects 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 239000011701 zinc Substances 0.000 abstract 1
- 229910052725 zinc Inorganic materials 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/04—Chelating agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
The present invention relates generally to a method of treating conditions characterised by aberrant amyloid precursor protein ferroxidase activity and agents useful for same. More particularly, the present invention relates to a method of treating conditions characterised by aberrant amyloid precursor protein ferroxidase activity by modulating amyloid precursor protein ferroxidase activity, in particular modulating the interaction of zinc or GFD with amyloid precursor protein. The method of the present invention is useful, inter alia, in the treatment and/or prophylaxis of conditions including, but not limited to, Alzheimer's disease.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2010903933A AU2010903933A0 (en) | 2010-09-01 | Method of treatment and agents useful for same | |
AU2010903933 | 2010-09-01 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2012027794A2 WO2012027794A2 (en) | 2012-03-08 |
WO2012027794A3 true WO2012027794A3 (en) | 2012-04-26 |
Family
ID=45773303
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/AU2011/001132 WO2012027794A2 (en) | 2010-09-01 | 2011-09-01 | Method of treatment and agents useful for same |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2012027794A2 (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL1866296T3 (en) | 2005-04-04 | 2017-05-31 | University Of Florida Research Foundation, Inc. | Desferrithiocin polyether analogues |
CA2680592C (en) | 2007-03-15 | 2016-07-05 | University Of Florida Research Foundation, Inc. | Desferrithiocin polyether analogues and uses thereof in treating pathological conditions |
WO2012142666A1 (en) * | 2011-04-19 | 2012-10-26 | The Mental Health Research Institute Of Victoria | Method of modulating amine oxidase activity and agents useful for same |
US20140343110A1 (en) | 2011-12-16 | 2014-11-20 | University Of Florida Research Foundation, Inc. | Uses of 4'-desferrithiocin analogs |
CA2930966A1 (en) | 2013-11-22 | 2015-05-28 | University Of Florida Research Foundation, Inc. | Desferrithiocin analogs and uses thereof |
US20180161295A1 (en) * | 2014-12-16 | 2018-06-14 | University Of Florida Research Foundation, Incorporated | Treatment of closed head injury and hemorrhagic stroke with hbed |
WO2016154682A1 (en) * | 2015-04-02 | 2016-10-06 | Crc For Mental Health Ltd | Method for predicting risk of cognitive deterioration |
KR20170140306A (en) | 2015-04-27 | 2017-12-20 | 유니버시티 오브 플로리다 리서치 파운데이션, 인코포레이티드 | Metabolically programmed metal chelating agents and uses thereof |
CN115275399B (en) * | 2022-08-30 | 2024-05-28 | 北京理工大学长三角研究院(嘉兴) | Electrolyte and aqueous zinc ion battery using same |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5705401A (en) * | 1991-11-12 | 1998-01-06 | The University Of Melbourne | Method of assaying for alzheimer's disease |
WO2003006044A1 (en) * | 2001-07-12 | 2003-01-23 | Novactyl, Inc. | Methods and compositions for controlling protein assembly or aggregation |
WO2005049026A1 (en) * | 2003-11-19 | 2005-06-02 | Acrux Dds Pty Ltd | Method and composition for treatment or prophylaxis of amyloidosis disorders |
-
2011
- 2011-09-01 WO PCT/AU2011/001132 patent/WO2012027794A2/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5705401A (en) * | 1991-11-12 | 1998-01-06 | The University Of Melbourne | Method of assaying for alzheimer's disease |
WO2003006044A1 (en) * | 2001-07-12 | 2003-01-23 | Novactyl, Inc. | Methods and compositions for controlling protein assembly or aggregation |
WO2005049026A1 (en) * | 2003-11-19 | 2005-06-02 | Acrux Dds Pty Ltd | Method and composition for treatment or prophylaxis of amyloidosis disorders |
Non-Patent Citations (2)
Title |
---|
BUSH A. I.: "Drug Development Based on the Metals Hypothesis of Alzheimer's Disease", JOURNAL OF ALZHEIMER'S DISEASE, vol. 15, 2008, pages 223 - 240 * |
FINEFROCK A. E. ET AL.: "Current Status of Metals as Therapeutic Targets in Alzheimer's Disease", JOURNAL OF THE AMERICAN GERIATRIC SOCIETY, vol. 51, no. 8, 2003, pages 1143 - 1148 * |
Also Published As
Publication number | Publication date |
---|---|
WO2012027794A2 (en) | 2012-03-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2012027794A3 (en) | Method of treatment and agents useful for same | |
USD914887S1 (en) | Wound dressing | |
EA201290041A1 (en) | TREATMENT OF DISORDERS ASSOCIATED WITH MACROPHAGES | |
MX2012000034A (en) | Methods for treating or preventing fatigue. | |
WO2012062925A3 (en) | Compounds and methods for treating pain | |
WO2011073279A3 (en) | Cosmetic treatment method involving a compound capable of condensing in situ | |
MY160894A (en) | Oligosaccharide composition for treating skin diseases | |
EA201490004A1 (en) | BIFIDOBACTERIUM LACTIS BL-04 APPLICATION FOR TREATMENT OF RESPIRATORY DISEASES | |
WO2012145651A3 (en) | Compounds for the treatment of neuropsychiatric disorders | |
WO2009089635A9 (en) | Treating neurodegenerative diseases with progranulin (pgrn) | |
WO2012050831A3 (en) | Combination treatment for dermatological conditions | |
WO2011140310A3 (en) | Povidone-iodine topical composition | |
NZ601350A (en) | Method of treating arthritis | |
WO2013098416A3 (en) | Pain relief compounds | |
WO2010088450A3 (en) | Arylamide derivatives useful in the treatment of diseases associated with serca activity | |
ATE538775T1 (en) | KETOROLAC-TROMETHAMIN COMPOSITIONS FOR THE TREATMENT OR PREVENTION OF PAIN | |
WO2013025744A3 (en) | Personal care methods comprising zinc pyrithione | |
WO2011089234A3 (en) | Aqueous solution comprising 3 - quinuclidinones for the treatment hyperproliferative, autoimmune and heart disease | |
WO2012076109A3 (en) | 2-pyrones | |
WO2012101156A3 (en) | Human lactoferrin based peptides having antiinflammatory activity | |
UA115128C2 (en) | Seed dressing for controlling phytopathogenic fungi | |
WO2009136997A3 (en) | Inhibitors of human cathepsin l, cathepsin b, and cathepsin s | |
MX2014014066A (en) | Chromane compounds. | |
CA2851761C (en) | Method of diagnosis, prognostic or treatment of neurodegenerative diseases | |
WO2010098583A2 (en) | Novel method for preparing statin compounds or salts thereof, and intermediate compounds used in same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11820926 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 11820926 Country of ref document: EP Kind code of ref document: A2 |